Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population

[1] Kirkman MS(2012)Diabetes in older adults: a consensus report J Am Geriatr Soc 60 2342-2356

[2] Briscoe VJ(2001)Clinical management of diabetes in the elderly Clin Diabetes 19 4-1053

[3] Clark N(2004)Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 1047-M13

[4] Florez H(2001)Diabetes in elderly adults J Gerontol A 56 M5-925

[5] Haas LB(2008)New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies Drugs Aging 25 913-442

[6] Halter JB(2015)Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 58 429-1736

[7] Chau D(2002)High-intensity resistance training improves glycemic control in older patients with type 2 diabetes Diabetes Care 25 1729-14

[8] Edelman SV(2013)Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings Diabetes Obes Metab 15 3-95

[9] Wild S(2004)Glucose metabolism and regulation: beyond insulin and glucagon Diabetes Spectrum. 17 8-677

[10] Roglic G(2011)Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database Diabetes Care 34 90-1133

[1] Kirkman MS(2012)Diabetes in older adults: a consensus report J Am Geriatr Soc 60 2342-2356

[2] Briscoe VJ(2001)Clinical management of diabetes in the elderly Clin Diabetes 19 4-1053

[3] Clark N(2004)Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 1047-M13

[4] Florez H(2001)Diabetes in elderly adults J Gerontol A 56 M5-925

[5] Haas LB(2008)New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies Drugs Aging 25 913-442

[6] Halter JB(2015)Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 58 429-1736

[7] Chau D(2002)High-intensity resistance training improves glycemic control in older patients with type 2 diabetes Diabetes Care 25 1729-14

[8] Edelman SV(2013)Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings Diabetes Obes Metab 15 3-95

[9] Wild S(2004)Glucose metabolism and regulation: beyond insulin and glucagon Diabetes Spectrum. 17 8-677

[10] Roglic G(2011)Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database Diabetes Care 34 90-1133